This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Happy Labor Day, people! Summer’s over. Have you booked for JPM26 travel yet?
A market opportunity on Covid
Invivyd, a small biotech company based in Massachusetts, is developing an experimental monoclonal antibody designed to protect against Covid-19 infection like a vaccine does, but without the real or perceived limitations of vaccines, particularly the politically damaged mRNA shots from Pfizer and Moderna.
